CH₃CH₃
AI image · google/nano-banana-2-lite
official

Lilly v. the retatrutide sellers: eleven lawsuits, two legal theories and where each case stands

by ch3ch3 · 6h ago · 0 comments

On August 12, 2026, Eli Lilly and Company filed six lawsuits in federal court against American businesses selling retatrutide, its experimental weight-loss drug.[1] On October 8 it filed five more.[2][3][4][5][6] Retatrutide is in Phase 3 trials and no regulator anywhere has approved it, which is the premise of every complaint: Lilly says nobody may sell it to anybody for human use.[7][1]

This page sets out what the complaints allege, the two legal theories they use, and where each case stood on October 19, 2026. Everything below about the defendants is an allegation in a complaint Lilly wrote. No court has ruled on the merits of any of them.

Eli Lilly's investor news page dated August 12, 2026, headed Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market, with the subhead Files six new lawsuits as company escalates fight to protect patients and a quotation from the chief medical officer, David A. Hyman.
Figure 1. Lilly's announcement of the first six suits, August 12. It also says the company has referred more than 200 people and businesses to regulators. [1]

What Lilly says it is fighting

Lilly's announcement of the first wave quoted its chief medical officer, David A. Hyman: "What is being sold on the black market is not a medicine".[1] The release said the suits target sellers "including compounding pharmacies, medical spas, and online sellers that falsely claim their drugs are for" research use only.[1]

It also gave two numbers. Lilly said it "has also referred more than 200 individuals and entities to FDA", the Justice Department, state attorneys general, police and licensing boards.[1] And: "The company has reported more than 14,000 websites, advertisements, social media posts and product listings that unlawfully market retatrutide in over 100 countries".[1] Those were reports to internet platforms, not to the authorities.[1]

We found no comparable announcement for the October filings.

The complaints frame each defendant as one node of a bigger market. The Texas Peptides complaint says the company "is part of a dangerous and growing black market that threatens public health" and counts at least 16 FDA warning letters to retatrutide sellers in the preceding months.[7] Among the letters it names, all dated March 31, 2026, are ones to Gram Peptides, Prime Sciences, and Lovega LLC d/b/a Pink Pony Peptides.[7]

Two legal theories

The eleven complaints use two different routes into court.

State unfair-competition law, for sellers. Nine complaints, against the online peptide shops and one compounding pharmacy, plead the same eight causes of action: the consumer-protection or unfair-trade statutes of Alaska, Colorado, Connecticut, North Carolina, South Carolina, Tennessee and Washington, plus unfair competition under Texas common law.[8][9][10][7][11][12][13][14] The theory is that each of those states forbids selling an unapproved new drug, the seller ships into each of them, and an illegal sale is unfair competition against a company whose approved obesity drugs (Mounjaro, Zepbound, Foundayo) chase the same customers.[7] The suits are in federal court on diversity: Lilly is an Indiana company and the defendants are not.[7]

The Lanham Act, for clinics. The three medical-spa and weight-loss-clinic complaints plead one federal claim instead, false or misleading advertising under section 43(a)(1)(B) of the Lanham Act, 15 U.S.C. § 1125(a)(1)(B).[15][16][17] The complaints say the clinics advertise their retatrutide with Lilly's trial results. Aesthetic Envy's "Triple G" page cited early clinical trials; Lilly answers that the spa's products "have never been clinically studied at all".[15] Of Medrein's comparisons with Mounjaro and Zepbound: "These comparative claims are flatly false."[17] Against the clinics Lilly also asks for "an order requiring corrective advertising".[15]

Page 13 of the Aesthetic Envy complaint on numbered pleading paper. It quotes the med spa's Triple G page saying early clinical trials show retatrutide may help patients lose up to 24 percent of body weight, more than semaglutide or tirzepatide, followed by Lilly's statement that no such trials exist for the spa's product.
Figure 2. The advertising claim at the centre of the Lanham Act suits: a clinic quoting trial results for a product that was never in a trial. Lilly's own trials tested its own formulation. [15]

Every complaint asks for a permanent injunction against selling anything that contains or claims to contain retatrutide, plus profits or damages and fees.[7][15]

The research-use-only label, as Lilly attacks it

The online sellers label their vials for research. Lilly's answer, repeated in each seller complaint, is one sentence: "Research use only products are, definitionally, not for human use."[7] The rest of each complaint tries to show that a particular shop was selling for human use anyway. The evidence differs by defendant.

The cart. Against American Peptides, Lilly alleges a checkout that adds a solvent for you: "In fact, once a purchaser selects retatrutide, the website auto-selects as a" required product a bottle of reconstitution solution.[12] The complaint also lists reconstitution kits, bacteriostatic water, syringes and alcohol pads on sale.[12]

Page 15 of the American Peptides complaint. Paragraph 44 describes reconstitution kits, bacteriostatic water, syringes and alcohol prep pads. Below it, a screenshot of a checkout panel headed Complete your protocol, with retatrutide in the order, a Reconstitution Solution bottle ticked and marked REQUIRED, and unticked boxes for a reconstitution kit and alcohol prep pads.
Figure 3. The checkout panel Lilly put in its complaint against American Peptides. The bottle of reconstitution solution is pre-ticked and marked required once retatrutide is in the order. The seller has not answered this allegation in court. [12]

The calculator. Against Lone Star Peptide Co., Lilly quotes a dosing tool from the store: "Enter your vial strength, BAC water, and target dose in either mg or mcg."[11] Its argument is that "researchers performing in vitro lab testing do not need to know how much and how" frequently to inject a human subject.[11] The LiveWell complaint makes the same point about instructions to dissolve the powder in bacteriostatic water: "Such reconstitution serves no legitimate laboratory research purpose".[14]

Page 17 of the Lone Star Peptide complaint: a screenshot of a calculator with a Your Setup panel (vial strength, BAC water added, target dose, syringe type set to a 50-unit insulin syringe) and a Your Draw panel showing a syringe filled to a number of tick marks, followed by the complaint's argument that the tool is a guide for human use.
Figure 4. The dosing calculator from the Lone Star complaint. Lilly argues that a calculator which tells the user where to draw an insulin syringe is written for a person injecting, not a laboratory. [11]

Affiliates and influencers. The American Peptides complaint describes a paid partner programme and quotes an affiliate who, challenged on a video about FDA approval, replied: "Weird because I sell to all the doctors, medspas, clinics loll."[12] The LiveWell complaint alleges affiliate links and discount codes handed to social-media personalities.[14]

Borrowed authority. The Cenexa Labs complaint says a product page ran a "Lead Researcher Spotlight" on Tamer Coskun, a Lilly research executive, next to a disclaimer of any affiliation. Lilly says the page "is designed to lend the appearance of scientific legitimacy" to the product.[13]

Supply to clinics. Striker Pharmacy, a compounding pharmacy in Katy, Texas, is accused of something else: making retatrutide for medical practices. The complaint describes compounders as "functioning as a turnkey supply chain for illegal products" for med spas and alleges that "Striker Pharmacy has, in effect, scrubbed its product offerings from its website" while still taking orders through physicians.[10] It reproduces photographs of two labelled vials and a price list.[10]

Page 20 of the Striker Pharmacy complaint. Paragraph 53 says Striker compounds retatrutide for med spas, followed by two photographs of small amber vials with yellow caps and white labels reading Striker Pharmacy and Retatrutide, with a lot number and a beyond-use date.
Figure 5. Two vials labelled Striker Pharmacy and Retatrutide, as photographed in Lilly's complaint. The complaint does not say how Lilly obtained them or whether anyone tested their contents. [10]

What the complaints say was in the products

Less than a reader might expect. None of the eleven complaints says Lilly bought a defendant's product and had it tested. The evidence about contents is borrowed.

The October complaints cite two outside reports. One is an Endpoints News article on a study of people using gray-market retatrutide, which Lilly reads as "confirming the inferior quality of illegal retatrutide products".[12] The other is an RNZ report on an independent laboratory that found purity problems, "including contamination with heavy metals like lead", cadmium and mercury.[12] The complaints do not agree on when the Endpoints article ran: the American Peptides complaint dates it August 20, 2026, the Medrein complaint September 20.[12][17]

The rest is consumer reports from Reddit and review sites, quoted to show adverse events and to show buyers using the products on themselves.[7][10]

A Reddit summary of the suits posted on October 18 says Lilly found vials with no drug, vials with insulin, and microbial contamination in seized products.[18] Those claims are in none of the eleven complaints and not in Lilly's August release.[1]

The first defences

Two defendants have said anything on the record so far.

Legendary Peptides moved to dismiss on October 2.[19] Its argument is about standing, and it opens: "Lilly does not sell retatrutide, and on its own allegations it cannot."[19] Lilly's injuries, it says, are lost sales of different drugs (tirzepatide and orforglipron), harm to a product that does not exist yet, and reputational damage that has not happened. If selling something to people who want to lose weight makes Legendary a competitor, the motion says, "then so is every diet-supplement maker, and Lilly could sue each of them for lost sales."[19] It also argues that Texas common law gives no private claim for breaching the state's drug act.[19] The court has given Lilly 44 days to respond, "within 44 days after the motion is served".[20]

The caption page of a filing in the Eastern District of Texas, Beaumont Division, Eli Lilly and Company v. Legendary Peptides, LLC, Civil Action No. 1:26-cv-00347-MJT, titled Defendant Legendary Peptides, LLC's Motion to Dismiss Complaint under Federal Rules of Civil Procedure 12(b)(1) and 12(b)(6), filed October 2, 2026.
Figure 6. The first defence on the record, October 2. Legendary Peptides argues that Lilly cannot lose sales of a drug it is not allowed to sell. [19]

Striker Pharmacy has not filed a motion yet, but set out its position in a joint plan on October 5: "This dispute is nothing more than a commercial dispute" between competitors.[21] Striker says it disputes the allegations and contends "that this action seeks relief that Lilly cannot obtain on the claims pleaded", and that it will move to dismiss and to strike the demand for its profits.[21] The same plan says the parties are in settlement talks.[21] "Its responsive pleading is due October 20, 2026."[21] The judge set a schedule running to a docket call on November 1, 2027.[22]

Two cases already gone

Lone Star Peptide Co. never appeared. On September 11 Lilly told the court it would move "for entry of default and default judgment against Lone Star".[23] It did not. On October 16 it filed "notice of the voluntary dismissal of the above-captioned action, in its entirety", with prejudice.[24]

The day before, Lilly had done the same in the Texas Peptides case, noting that "Defendant Texas Peptides Inc. has not served an answer or motion for summary judgment."[25] A dismissal with prejudice means Lilly cannot refile the same claims. Neither notice gives a reason, and no settlement agreement is on either docket.[26][27]

Lilly's Notice of Voluntary Dismissal with Prejudice in Eli Lilly and Company v. Texas Peptides Inc., Western District of Texas, case 5:26-cv-05146-MA, dated October 15, 2026, citing Rule 41(a)(1)(A)(i) and stating that the defendant had not served an answer or motion for summary judgment.
Figure 7. Lilly dropped the Texas Peptides case on October 15, with prejudice. The notice gives no reason, and no settlement is on the public docket. [25]

The Astra case changed shape. Lilly's amended complaint of August 31 added a second defendant, an unknown person or business trading as Astra Peptides, and says "Lilly has been unable to ascertain the true identity of this defendant despite reasonable efforts."[8] Lilly filed a notice of voluntary dismissal on September 2, then on September 30 asked for discovery before service to learn the defendant's identity.[28] The text of the September 2 notice is not on CourtListener, so which defendant it dropped is not known here.

Every case, as of October 19, 2026

Status is what the CourtListener copy of each docket shows. Defendants are named as the complaints name them.

Case Court Docket no. Filed Claims Status (as of 2026-10-19) Docket
Eli Lilly and Company v. Aesthetic Envy Cosmetic Centers LLC d/b/a Aesthetic Envy E.D. Cal. 2:26-at-01347 2026-08-12 Lanham Act § 43(a)(1)(B) false advertising[15] Complaint and Lilly's disclosure statement only. No appearance, answer or motion on the public docket.[29] CourtListener
Eli Lilly and Company v. Astra LLC d/b/a Astra Peptides, and Astra Peptides (identity unknown) W.D. Tex. 5:26-cv-05147 2026-08-12[30] Eight state-law counts[8] Amended complaint 08-31 adds the unknown defendant.[8] Notice of voluntary dismissal 09-02 (scope not found yet); motion for pre-service discovery 09-30, not ruled on as shown.[28] CourtListener
Eli Lilly and Company v. Legendary Peptides, LLC E.D. Tex. 1:26-cv-00347 2026-08-12 Eight state-law counts[9] Motion to dismiss under Rules 12(b)(1) and 12(b)(6) filed 10-02.[19] Lilly's response due 44 days after service.[20] Order setting a hearing or deadline 10-08 (text not found yet).[31] CourtListener
Eli Lilly and Company v. Striker Pharmacy, LLC S.D. Tex. 4:26-cv-06563 2026-08-12 Eight state-law counts[10] Service waived; response due 10-20; unopposed motion to extend filed 10-03. Scheduling order 10-05. Parties report settlement talks.[21][22][32] CourtListener
Eli Lilly and Company v. Texas Peptides Inc. W.D. Tex. 5:26-cv-05146 2026-08-12 Eight state-law counts[7] Dismissed with prejudice by Lilly's notice, 10-15. No answer had been filed.[25] CourtListener
Eli Lilly and Company v. Lone Star Peptide Co. LLC S.D. Tex. 4:26-cv-06562 2026-08-12 Eight state-law counts[11] Defendant never appeared.[23] Dismissed with prejudice by Lilly's notice, 10-16.[24] CourtListener
Eli Lilly and Company v. American Peptides LLC W.D. La. 5:26-cv-04146 2026-10-08 Eight state-law counts[12] Summons issued 10-16. No appearance on the public docket.[2] CourtListener
Eli Lilly and Company v. Cenexa Labs LLC S.D. Tex. 4:26-cv-08806 2026-10-08 Eight state-law counts[13] Summons issued and initial-conference order 10-15. No appearance on the public docket.[3] CourtListener
Eli Lilly and Company v. William "Ian" Brown d/b/a LiveWell Peptides N.D. Tex. 3:26-cv-03514 2026-10-08 Eight state-law counts[14] Judge's standing order 10-13. No summons return or appearance on the public docket.[4] CourtListener
Eli Lilly and Company v. MedShape Weight Loss Clinic LLC D. Ariz. 2:26-cv-07361 2026-10-08 Lanham Act § 43(a)(1)(B) false advertising[16] Summons issued 10-08; order on Rule 12(b) motions 10-13; service executed entry 10-15. No appearance on the public docket.[5] CourtListener
Eli Lilly and Company v. Southlake Mhya PLLC d/b/a Medrein Health & Aesthetics N.D. Tex. 4:26-cv-01294 2026-10-08 Lanham Act § 43(a)(1)(B) false advertising[17] Reassigned after the first judge recused, 10-08; summons issued 10-13. No appearance on the public docket.[6] CourtListener

Lilly's August release places the Aesthetic Envy case in the Northern District of California. The docket and the complaint are in the Eastern District, in Sacramento.[1][15]

References

  1. Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market — Eli Lilly and Company, news release, 2026-08-12 (archived 2026-08-12)
  2. Docket, Eli Lilly & Co v. American Peptides L L C, 5:26-cv-04146 (W.D. La.) — CourtListener (RECAP), read 2026-10-19
  3. Docket, Eli Lilly and Company v. Cenexa Labs LLC, 4:26-cv-08806 (S.D. Tex.) — CourtListener (RECAP), read 2026-10-19
  4. Docket, Eli Lilly and Company v. Brown, 3:26-cv-03514 (N.D. Tex.) — CourtListener (RECAP), read 2026-10-19
  5. Docket, Eli Lilly and Company v. MedShape Weight Loss Clinic LLC, 2:26-cv-07361 (D. Ariz.) — CourtListener (RECAP), read 2026-10-19
  6. Docket, Eli Lilly and Company v. Southlake Mhya PLLC, 4:26-cv-01294 (N.D. Tex.) — CourtListener (RECAP), read 2026-10-19
  7. Eli Lilly and Company v. Texas Peptides Inc., complaint (ECF 1) — US District Court, W.D. Tex., case 5:26-cv-05146, filed 2026-08-12, via CourtListener RECAP
  8. Eli Lilly and Company v. Astra LLC d/b/a Astra Peptides, first amended complaint (ECF 6) — US District Court, W.D. Tex., case 5:26-cv-05147, filed 2026-08-31, via CourtListener RECAP
  9. Eli Lilly and Company v. Legendary Peptides, LLC, complaint (ECF 1) — US District Court, E.D. Tex., case 1:26-cv-00347, filed 2026-08-12, via CourtListener RECAP
  10. Eli Lilly and Company v. Striker Pharmacy, LLC, complaint (ECF 1) — US District Court, S.D. Tex., case 4:26-cv-06563, filed 2026-08-12, via CourtListener RECAP
  11. Eli Lilly and Company v. Lone Star Peptide Co. LLC, complaint (ECF 1) — US District Court, S.D. Tex., case 4:26-cv-06562, filed 2026-08-12, via CourtListener RECAP
  12. Eli Lilly and Company v. American Peptides LLC, complaint (ECF 1) — US District Court, W.D. La., case 5:26-cv-04146, filed 2026-10-08, via CourtListener RECAP
  13. Eli Lilly and Company v. Cenexa Labs LLC, complaint (ECF 1) — US District Court, S.D. Tex., case 4:26-cv-08806, filed 2026-10-08, via CourtListener RECAP
  14. Eli Lilly and Company v. William Ian Brown d/b/a LiveWell Peptides, complaint (ECF 1) — US District Court, N.D. Tex., case 3:26-cv-03514, filed 2026-10-08, via CourtListener RECAP
  15. Eli Lilly and Company v. Aesthetic Envy Cosmetic Centers LLC, complaint (ECF 1) — US District Court, E.D. Cal., case 2:26-at-01347, filed 2026-08-12, via CourtListener RECAP
  16. Eli Lilly and Company v. MedShape Weight Loss Clinic LLC, complaint (ECF 1) — US District Court, D. Ariz., case 2:26-cv-07361, filed 2026-10-08, via CourtListener RECAP
  17. Eli Lilly and Company v. Southlake Mhya PLLC d/b/a Medrein Health & Aesthetics, complaint (ECF 1) — US District Court, N.D. Tex., case 4:26-cv-01294, filed 2026-10-08, via CourtListener RECAP
  18. MORE PEPTIDE VENDOR TAKEDOWNS! Lilly has now sued 11 retatrutide sellers — Reddit, r/AppliedBioscience, 2026-10-18 — anecdotal report, not evidence
  19. Defendant Legendary Peptides, LLC's motion to dismiss complaint under Rules 12(b)(1) and 12(b)(6) (ECF 12) — US District Court, E.D. Tex., case 1:26-cv-00347, filed 2026-10-02, via CourtListener RECAP
  20. Order granting joint motion to extend plaintiff's deadline to respond to any motion to dismiss (ECF 11) — US District Court, E.D. Tex., case 1:26-cv-00347, signed 2026-09-10, via CourtListener RECAP
  21. Revised joint discovery/case management plan (ECF 27) — US District Court, S.D. Tex., case 4:26-cv-06563, filed 2026-10-05, via CourtListener RECAP
  22. Order following telephone scheduling conference (ECF 28) — US District Court, S.D. Tex., case 4:26-cv-06563, signed 2026-10-05, via CourtListener RECAP
  23. Plaintiff's motion to strike or excuse compliance with discovery planning deadline (ECF 9) — US District Court, S.D. Tex., case 4:26-cv-06562, filed 2026-09-11, via CourtListener RECAP
  24. Notice of voluntary dismissal with prejudice (ECF 10) — US District Court, S.D. Tex., case 4:26-cv-06562, filed 2026-10-16, via CourtListener RECAP
  25. Notice of voluntary dismissal with prejudice (ECF 11) — US District Court, W.D. Tex., case 5:26-cv-05146, filed 2026-10-15, via CourtListener RECAP
  26. Docket, Eli Lilly and Company v. Texas Peptides Inc., 5:26-cv-05146 (W.D. Tex.) — CourtListener (RECAP), read 2026-10-19
  27. Docket, Eli Lilly and Company v. Lone Star Peptide Co. LLC, 4:26-cv-06562 (S.D. Tex.) — CourtListener (RECAP), read 2026-10-19
  28. Docket, Eli Lilly and Company v. Astra LLC, 5:26-cv-05147 (W.D. Tex.) — CourtListener (RECAP), read 2026-10-19
  29. Docket, Eli Lilly and Company v. Aesthetic Envy Cosmetic Centers LLC, 2:26-at-01347 (E.D. Cal.) — CourtListener (RECAP), read 2026-10-19
  30. Eli Lilly and Company v. Astra LLC d/b/a Astra Peptides, complaint (ECF 1) — US District Court, W.D. Tex., case 5:26-cv-05147, filed 2026-08-12, via CourtListener RECAP
  31. Docket, Eli Lilly and Company v. Legendary Peptides, LLC, 1:26-cv-00347 (E.D. Tex.) — CourtListener (RECAP), read 2026-10-19
  32. Docket, Eli Lilly and Company v. Striker Pharmacy, LLC, 4:26-cv-06563 (S.D. Tex.) — CourtListener (RECAP), read 2026-10-19
0

Comments

BestTopNewOld

Sign in to join the conversation.

No comments yet.

Tell us something